Critical role for activation of antigen-presenting cells in priming of cytotoxic T cell responses after vaccination with virus-like particles.
about
Plant Viruses as Nanoparticle-Based Vaccines and AdjuvantsScavenger Receptor Class B Is Required for Hepatitis C Virus Uptake and Cross-Presentation by Human Dendritic CellsSecretory phospholipase A2-IID is an effector molecule of CD4+CD25+ regulatory T cellsExploiting virus-like particles as innovative vaccines against emerging viral infectionsVirus-like particles as universal influenza vaccinesContribution of virus-like particles to the immunogenicity of human immunodeficiency virus type 1 Gag-derived vaccines in miceAn RNA vaccine based on recombinant Semliki Forest virus particles expressing the Cu,Zn superoxide dismutase protein of Brucella abortus induces protective immunity in BALB/c mice.Construction and immunological evaluation of multivalent hepatitis B virus (HBV) core virus-like particles carrying HBV and HCV epitopes.Incorporation of CD40 ligand into SHIV virus-like particles (VLP) enhances SHIV-VLP-induced dendritic cell activation and boosts immune responses against HIV.Innate signals compensate for the absence of PKC-{theta} during in vivo CD8(+) T cell effector and memory responsesCritical role of TLR7 signaling in the priming of cross-protective cytotoxic T lymphocyte responses by a whole inactivated influenza virus vaccine.Uncertainties - discrepancies in immunology.Bacterially produced recombinant influenza vaccines based on virus-like particles.An engineered non-toxic superantigen increases cross presentation of hepatitis B virus nucleocapsids by human dendritic cells.Enhancing the immunogenicity of tumour lysate-loaded dendritic cell vaccines by conjugation to virus-like particles.Development of virus-like particles for diagnostic and prophylactic biomedical applicationsTherapeutic polypeptides based on HBcAg(18-27) CTL epitope can induce antigen-specific CD(8)(+) CTL-mediated cytotoxicity in HLA-A2 transgenic mice.Novel plant virus-based vaccine induces protective cytotoxic T-lymphocyte-mediated antiviral immunity through dendritic cell maturation.Therapeutic targeting of innate immunity with Toll-like receptor agonists and antagonists.Endogenous neosynthesis vs. cross-presentation of viral antigens for cytotoxic T cell primingEngineering virus-like particles as vaccine platformsBacterium-like particles for efficient immune stimulation of existing vaccines and new subunit vaccines in mucosal applicationsThe coming of age of virus-like particle vaccines.Virus-like particles as carriers for T-cell epitopes: limited inhibition of T-cell priming by carrier-specific antibodies.Developments in virus-like particle-based vaccines for HIV.Advances and challenges in the development and production of effective plant-based influenza vaccines.Tailoring Biomaterials for Cancer Immunotherapy: Emerging Trends and Future Outlook.Biomedical and Catalytic Opportunities of Virus-Like Particles in Nanotechnology.Advanced antigen delivery of murine survivin: chimeric virus-like particles in cancer vaccine researchProtective T Cell and Antibody Immune Responses against Hepatitis C Virus Achieved Using a Biopolyester-Bead-Based Vaccine Delivery System.Paradoxical enhancement of CD8 T cell-dependent anti-tumor protection despite reduced CD8 T cell responses with addition of a TLR9 agonist to a tumor vaccine.Liposomes and nanotechnology in drug development: focus on oncotargets.Versatile RHDV virus-like particles: incorporation of antigens by genetic modification and chemical conjugation.Efficient homologous prime-boost strategies for T cell vaccination based on virus-like particles.
P2860
Q26782569-6EF655F1-5772-4846-BD63-8D5AB4727336Q27485559-5DE2F707-DBED-49CB-A0D8-D8E14436759CQ28512213-CCEFE339-AC7A-4F84-AFE8-63D620ED774DQ29365799-7FEA20C6-E5F8-40CF-B3A7-D838C7558835Q30421558-B4F82939-C8EB-4A47-AFD5-E198A2F3FE30Q33717736-9B2D6695-BDDC-499A-ADEC-C1D48B824CADQ33788131-3FD02DF6-A3A8-4FF9-BF96-4161200FDB17Q33909134-089AFBC1-48EC-4F44-A3C8-A430EBF336E9Q34005446-46621E0E-0E0E-49EF-8287-BE9A5BD911DDQ34063599-68E5C6BC-7E7A-49E5-954C-EDF6E3D604DAQ34712969-669611BD-972D-449F-8797-ADFD4F533F92Q34792441-A347E1B0-6271-4B53-8E6E-88A3C33364CCQ35048127-6BE26A94-4FCE-4055-9C29-B579FF845DDAQ35137191-50325CC0-9BC5-4B1F-95DF-7B7CBC3E6AF2Q35653886-51434F44-36EA-4A35-9259-401F6DE1149FQ35889469-A7A9D5AD-D9D2-459F-B876-E40535010ED9Q36308346-3C741899-2237-455C-8FE6-713121940F48Q36424493-1E0D0182-9A99-42C9-92EE-0D4918A0A324Q36811131-B6A2AD7D-E7E0-47A2-80BA-434A5CA567A8Q37089414-6C887590-E5A1-4B6A-87B0-8FC6279E3F3BQ37172342-6311476A-678E-4944-961C-D6C6F3F0E374Q37177598-6E524AE2-C633-4E27-8DEB-2A8B4778F875Q37309265-D105B977-938F-4256-81B7-8FE21E04ABB1Q37743908-190B2AC6-E1E0-4FCD-9A1A-15D3BCCAF46DQ38081965-F65408FB-AA7C-43F8-99EC-545C2F8C1CFDQ38285425-BB28BF62-C79F-48E0-A7F4-4311049D1E5BQ38677432-FF1475DD-4CA4-4229-94F5-4C846F8C42B6Q39068831-59639F00-0DD0-4445-AF1D-43977E074176Q39526556-831A46BD-D461-46C1-8B71-42BF85E09A7DQ39860495-14FC75FB-57EC-404A-915E-0015F57CE452Q40120516-707E6F92-1519-4F31-9F84-B28738779230Q41980659-9AC77E8B-647D-48A4-926E-9E2133C7BC12Q45403336-BF713A28-276E-4635-9D2E-9EFF28AC0223Q45508859-52E30FC1-ED56-4CEE-B64B-C278227D80A7
P2860
Critical role for activation of antigen-presenting cells in priming of cytotoxic T cell responses after vaccination with virus-like particles.
description
2002 nî lūn-bûn
@nan
2002年の論文
@ja
2002年論文
@yue
2002年論文
@zh-hant
2002年論文
@zh-hk
2002年論文
@zh-mo
2002年論文
@zh-tw
2002年论文
@wuu
2002年论文
@zh
2002年论文
@zh-cn
name
Critical role for activation o ...... ion with virus-like particles.
@en
type
label
Critical role for activation o ...... ion with virus-like particles.
@en
prefLabel
Critical role for activation o ...... ion with virus-like particles.
@en
P2093
P1476
Critical role for activation o ...... ion with virus-like particles.
@en
P2093
Andrea Jegerlehner
Christiane Ruedl
Franziska Lechner
Iris Erdmann
Martin F Bachmann
Tazio Storni
Thomas Bächi
Thomas M Kündig
Tilman Dumrese
P304
P356
10.4049/JIMMUNOL.168.6.2880
P407
P577
2002-03-01T00:00:00Z